234 related articles for article (PubMed ID: 24399717)
1. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
2. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Kabel AM; Omar MS; Alhadhrami A; Alharthi SS; Alrobaian MM
Physiol Behav; 2018 May; 188():108-118. PubMed ID: 29410018
[TBL] [Abstract][Full Text] [Related]
5. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
8. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
[TBL] [Abstract][Full Text] [Related]
9. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
10. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
11. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Viaro R; Marti M; Morari M
Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
[TBL] [Abstract][Full Text] [Related]
12. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
[TBL] [Abstract][Full Text] [Related]
13. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Carta AR; Pinna A; Tronci E; Morelli M
Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Frouni I; Kwan C; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2139-2144. PubMed ID: 32601846
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.
Thomas B; Saravanan KS; Mohanakumar KP
Neurochem Int; 2008 May; 52(6):990-1001. PubMed ID: 18164516
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Fredriksson A; Danysz W; Quack G; Archer T
J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
[TBL] [Abstract][Full Text] [Related]
19. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Liu Q; Zhang S; Zhu D; Tang X; Che Y; Feng X
Behav Brain Res; 2020 Feb; 379():112337. PubMed ID: 31697983
[TBL] [Abstract][Full Text] [Related]
20. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
